Contineum Stock Price Drops 9.9% Following Failure of Mid-term Trials for Depression Drug Collaborated with Johnson & Johnson
2026-09-16 01:19:49
According to CoinMeta, as reported by Reuters, the stock price of Contineum fell by 9.9% due to the failure of a depression drug in collaboration with Johnson & Johnson during the mid-stage trials.
Bullish 0
Bearish 0
Source:Internet
This content is for market information only and does not constitute investment advice.